Detailed company information
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 28, 2026
Earnings Transcript for 2026 - Q1Released: Apr 28, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Oct 28, 2025
Earnings Transcript for 2025 - Q2Released: Jul 29, 2025
Earnings Transcript for 2025 - Q1Released: Apr 29, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Oct 29, 2024
Earnings Transcript for 2024 - Q2Released: Jul 23, 2024
Earnings Transcript for 2024 - Q1Released: Apr 23, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Oct 31, 2023
Earnings Transcript for 2023 - Q2Released: Jul 25, 2023
Earnings Transcript for 2023 - Q1Released: May 06, 2023
Earnings Transcript for 2022 - Q4Released: Feb 28, 2023
Earnings Transcript for 2022 - Q3Released: Nov 01, 2022
Earnings Transcript for 2022 - Q2Released: Aug 05, 2022
Earnings Transcript for 2022 - Q1Released: May 07, 2022
Earnings Transcript for 2021 - Q4Released: Feb 22, 2022
Earnings Transcript for 2021 - Q3Released: Nov 01, 2021
Earnings Transcript for 2021 - Q2Released: Aug 03, 2021
GOSS Gossamer Bio, Inc.
CGEM Cullinan Therapeutics, Inc.
CHRS Coherus Oncology, Inc.
COGT Cogent Biosciences, Inc.
KURA Kura Oncology, Inc.
REPL Replimune Group, Inc.
CYTK Cytokinetics, Incorporated
KROS Keros Therapeutics, Inc.
XERS Xeris Biopharma Holdings, Inc.
NKTR Nektar Therapeutics
BMRN BioMarin Pharmaceutical Inc.
IONS Ionis Pharmaceuticals, Inc.
Dafinchi